Free
Original Contribution  |   May 2020
Regular Mindful Yoga Practice as a Method to Improve Androgen Levels in Women With Polycystic Ovary Syndrome: A Randomized, Controlled Trial
Author Notes
  • From the Department of Biochemistry at the Lake Erie College of Osteopathic Medicine in Pennsylvania (Student Drs Patel, Menezes, Menezes, and Bouwer, and Dr Speelman) and Medical Associates of Erie, Pennsylvania (Dr Bostick-Smith). 
  • Financial disclosures: None reported. 
  • Support: This work was funded by AOA Grant No. 181627705 to Diana Speelman, PhD. 
  •  *Address correspondence to: Diana Speelman, PhD, Lake Erie College of Osteopathic Medicine, 2000 W Grandview Blvd, Erie, PA 16509-1029. Email: dspeelman@lecom.edu
     
Article Information
Endocrinology / Obstetrics and Gynecology
Original Contribution   |   May 2020
Regular Mindful Yoga Practice as a Method to Improve Androgen Levels in Women With Polycystic Ovary Syndrome: A Randomized, Controlled Trial
The Journal of the American Osteopathic Association, May 2020, Vol. 120, 323-335. doi:https://doi.org/10.7556/jaoa.2020.050
The Journal of the American Osteopathic Association, May 2020, Vol. 120, 323-335. doi:https://doi.org/10.7556/jaoa.2020.050
Web of Science® Times Cited: 1
Abstract

Background: Holistic approaches are needed to complement existing therapies for polycystic ovary syndrome (PCOS), a common disorder affecting the health of reproductive-aged females.

Objective: To determine whether thrice-weekly mindful yoga practice improves endocrine, cardiometabolic, or psychological parameters in women with PCOS.

Methods: Thirty-one women with PCOS between the ages of 23 and 42 years and living in Erie County, Pennsylvania, were recruited for this randomized, controlled study arm, which was part of a larger 3-part investigation. Women were randomly assigned to either a mindful yoga intervention group or no intervention (control) group. Group classes were 1 hour, thrice weekly. Initial endocrine, cardiometabolic, and psychological measurements were compared with measurements taken after the 3-month intervention period. Measurements included free testosterone, dehydroepiandrosterone, androstenedione, body mass index, waist-to-hip ratio, fasting blood glucose and insulin levels, and anxiety and depression scores.

Results: Twenty-two women completed the 3-month intervention period, 13 in the mindful yoga group and 9 in the control group. Paired comparisons of pre- and postintervention parameters indicated that women who completed the mindful yoga intervention had significantly lower free testosterone levels (5.96 vs 4.24 pg/mL; P<.05) and dehydroepiandrosterone levels that trended lower. Improved testosterone may persist for several months after completion of a 3-month, thrice-weekly mindful yoga intervention. Additionally, improvements were seen in measures of anxiety and depression.

Conclusion: The improvements observed suggest that regular mindful yoga practice can be a useful complementary therapeutic option for women with PCOS, particularly for improving serum androgen levels, a hallmark feature of PCOS. This improvement occurred in the absence of weight loss and may persist even if there is a lapse in practice. (ClinicalTrials.gov No. NCT03383484)

The most common endocrine and metabolic disorder in women, polycystic ovary syndrome (PCOS), affects 5% to 15% of women of reproductive age and is the most common cause of anovulatory infertility.1,2 The triad of defining PCOS features includes hyperandrogenism (clinical or biochemical), menstrual irregularity secondary to oligo-ovulation or anovulation, and polycystic ovary morphology. The Rotterdam criteria, most often used for diagnosis, include the presence of at least 2 of the above criteria, along with exclusion of other diseases and conditions that may produce similar features, including but not limited to disorders involving adrenal hormones, thyroid hormone, or prolactin.3 Women with PCOS may present with hirsutism, acne, male-pattern hair loss, subfertility, and greater incidence of miscarriage.4,5 
Cardiometabolic and Psychological Impact of PCOS
Polycystic ovary syndrome can affect women's health beyond the reproductive years. Women with PCOS commonly exhibit excessive weight gain, glucose intolerance, and insulin resistance, abnormal adipokine secretion, and are more likely to develop type 2 diabetes mellitus and cardiovascular sequelae.6-8 Insulin and androgens are reported to have a reciprocal relationship in PCOS, with an elevation in either hormone stimulating an increase in the other, further perpetuating the pathogenesis of the disorder.9-11 Obesity exacerbates the severity of PCOS and increases the risk of related sequelae, although lean women with PCOS are also reported to have insulin resistance and altered adipokine secretion, indicative of metabolic dysfunction even in the absence of obesity in this population.12-16 Women with PCOS are also reported to be more likely to experience anxiety and depression.17,18 Taken together, PCOS has the potential to affect long-term health and quality of life.19 
Therapies for PCOS
Despite its prevalence and impact on female health, the cause of PCOS remains unknown. Weight loss of 5% to 10% can improve menstrual regularity, androgen levels, and possibly fertility in obese young adult women with PCOS, and is the first-line therapy.14,20,21 However, there are often hurdles to achieving and maintaining weight loss. Current pharmacologic therapies typically target individual symptoms, such as reducing elevated androgens with anti-androgenic medications, regulating the menstrual cycle with hormonal contraceptives, and using ovulation inducers to increase the likelihood of conception.22,23 However, pharmacologic interventions are limited in their scope and may result in adverse effects as well as increased risk for developing complications such as thrombosis and breast and cervical cancer (although ovarian and endometrial cancer risk is lower).24,25 Recent surveys of women with PCOS indicated that these women are interested in complementary or alternative options for treating their symptoms.26,27 Reasons cited include strong dissatisfaction with pharmaceutical therapies, desire for an effective and safe alternative to hormonal contraception and fertility drugs, and desire for more than single symptom management. Existing nonpharmacologic options for women with PCOS are dietary modification (including reduced carbohydrate intake) to promote a reduction in serum insulin levels,28,29 nutritional and herbal supplements,26,30 acupuncture,31,32 and aerobic exercise to promote weight loss.14,29,33-35 
Yoga is a low-impact exercise that does not require the individual to have a specific level of fitness or flexibility to participate or benefit from the practice. It has been used as a therapy for many different conditions, including hypertension, multiple sclerosis, asthma, low back pain, arthritis, and for pain and stress management; its therapeutic mechanism has been attributed to decreased sympathetic tone, cortisol, and stress levels.36-42 While moderate aerobic exercise improves cardiometabolic and reproductive parameters in women with PCOS, a major benefit of yoga is that it is accessible to individuals of varying fitness levels who may be uncomfortable with more intense aerobic activity. In addition, yoga promotes mindfulness in the participant, including awareness of the body's posture and breathing.43 Elements of mindfulness can be applied not only in yoga practice, but may also be reinforced in daily activities to promote relaxation and focus. Studies44,45 on the effects of yoga on females with PCOS have reported improved insulin sensitivity and lipid profiles, but were limited to a study population of adolescent females without biochemical hyperandrogenism. In addition, these studies required daily yoga for 1 hour over a 3-month period. While these results were promising, the more realistic practice of yoga several times per week or by women with PCOS were not explored. In the current study, we examined the effects of 3 months of thrice-weekly mindful yoga practice on the metabolic, endocrine, and reproductive health of women with PCOS. The primary aim was to determine whether regular mindful yoga practice would decrease androgen levels, with a primary outcome measure of serum testosterone level. The secondary aim was to determine whether regular mindful yoga practice would decrease other common reproductive, metabolic, and psychological factors associated with PCOS; thus, the secondary outcome measures included menstrual cycle length, Ferriman-Gallwey score, weak androgens, fasting blood glucose and insulin, adiponectin, waist-to-hip ratio, body mass index (BMI), and scores for anxiety and depression. Furthermore, we investigated whether the benefits observed with the regular mindful yoga practice persisted beyond the completion of the 3-month intervention period. 
Methods
All protocols were approved by the Lake Erie College of Osteopathic Medicine institutional review board (protocol #23-156). This was a separate arm of a larger study, results from which are also reported in the May issue of The Journal of the American Osteopathic Association and participant recruitment for which occurred during the same time period.46 (ClinicalTrials.gov No. NCT03383484) 
Participant Recruitment and Consent
Study participants were recruited from the Erie, Pennsylvania, area by direct advertising through radio, billboards, website, newspaper, and magazine ads. Physician referrals from Medical Associates of Erie providers were also used to recruit potential participants. Recruitment lasted 4 months, from October 2016 through January 2017. Potential participants signed a consent form to have relevant medical records released to confirm PCOS diagnosis, as well as informed consent to participate in the study. 
Participant Inclusion and Exclusion
A participant questionnaire was given at the time of consent to supplement the medical records in order to determine eligibility. Participants were premenopausal women between the ages of 22 and 43 years, with a BMI of 20 to 48, who had a confirmed diagnosis of PCOS, and exhibited the 2003 Rotterdam criteria for PCOS diagnosis, defined as at least 2 of the following 3 features: clinical or biochemical hyperandrogenism (moderate acne or a modified Ferriman-Gallwey [mFG] score >8 or free testosterone >5 pg/mL), polycystic ovaries (≤12 cysts on 1 ovary by ultrasonography or ovarian volume >10 mL for 1 ovary), and menstrual irregularity (defined as ≤8 menstrual periods per year or cycles averaging >35 days).47 Exclusion criteria included smoking, use of hormone-based medications within the past 3 months (hormonal contraception, ovulation inducers, antiandrogens) or insulin-sensitizing agents, presence of another endocrine disorder diagnosis, pregnancy or breastfeeding within the past 6 months, or diagnosis of a major psychiatric disorder or use of antipsychotic medication. None of the participants practiced yoga or received osteopathic manipulative treatment or acupuncture within the 6 months before the study. 
Study Design, Participant Attrition, and Protocol Deviations
Participants were enrolled in the study after confirming eligibility according to inclusion and exclusion criteria. All participants were randomly assigned a unique, sequential number to allow for random assignment to a group (no intervention [control], mindful yoga, or OMT; the latter is reported elsewhere the May issue of The Journal of the American Osteopathic Association). After group assignment but before the intervention period began, 10 of the 55 participants withdrew from the study, citing the following reasons: group assigned was not desired (6, most citing desire to be in the yoga group); inability to make the time commitment for attendance of the yoga group class (3); and personal reasons (1). More participants were placed in the mindful yoga intervention group, in anticipation of attrition during the intervention period (Figure).48 
Figure.
Study design overview and timeline. Women with polycystic ovary syndrome (PCOS) were recruited from the Erie, PA, area using media advertising. After informed consent to participate in the study and release medical records, eligibility was determined according to inclusion and exclusion criteria, using Rotterdam criteria, and a questionnaire. Participants (N=13) were randomly assigned to the no intervention (control) or mindful yoga intervention group. Thirty-one participants were enrolled in the study, and 22 completed the 3-month intervention period and postintervention measurements. An additional 14 participants were included in a separate arm of the study assessing osteopathic manipulative treatment (OMT) for sympathetic tone in women with PCOS.46
Figure.
Study design overview and timeline. Women with polycystic ovary syndrome (PCOS) were recruited from the Erie, PA, area using media advertising. After informed consent to participate in the study and release medical records, eligibility was determined according to inclusion and exclusion criteria, using Rotterdam criteria, and a questionnaire. Participants (N=13) were randomly assigned to the no intervention (control) or mindful yoga intervention group. Thirty-one participants were enrolled in the study, and 22 completed the 3-month intervention period and postintervention measurements. An additional 14 participants were included in a separate arm of the study assessing osteopathic manipulative treatment (OMT) for sympathetic tone in women with PCOS.46
Protocol deviations included participant noncompliance (failure to complete initial or 3-month measurements, failure to attend group mindful yoga classes 3 times per week, and discontinuation of the intervention). No deviation from the mindful yoga methods protocol occurred. No protocol violations occurred.49 
Data Collection
Participants used their assigned number (above) for identification during data collection. Investigators collecting participant data were blinded to participant intervention group (V.P., C.M., H.M., S.B., C.B.S.). De-identified participant data were stored in a secure database. 
Clinical Assessment
In January 2017, before the intervention period, a gynecologist (C.B.S.) who was blinded to the assigned intervention group assessed participants' weight, height, BMI, blood pressure, heart rate, waist and hip circumference, hirsutism (mFG score), and acne (face, chest, and back) in a physicians' office. Patients were asked about their menstrual cycle history and pattern (<25 days, 25-35 days, or >35 days), pregnancies, and any medications that they had taken within the past 6 months. Participants had peripheral venous blood collected while fasting to measure the following: glucose, insulin, adiponectin, free testosterone, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), androstenedione (A4), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, thyroid-stimulating hormone, and human chorionic gonadotropin (hCG) levels. Patients completed secure online questionnaires for anxiety (Beck Anxiety Inventory [BAI], Pearson Global) and depression (Beck Depression Inventory-II [BDI-II], Pearson Global). 
Postintervention measurements were taken in May 2017 for participants in both the control group and the mindful yoga intervention group (for those who regularly attended, defined as ≤2 classes each week), within 1 week after conclusion of the 3-month intervention. The mindful yoga intervention group participants also had their free testosterone, DHEA, and adiponectin measured again in August 2017, 3 months after conclusion of the 3-month intervention, to determine whether significant postintervention changes persisted over time. 
Serum Analysis
All participants had pre- and postintervention fasting venous blood draws. All whole blood samples were collected by Associated Clinical Laboratories and analyzed by Associated Clinical Laboratories or Quest Diagnostics. Fasting blood glucose was measured by spectrophotometry; adiponectin was determined by an enzyme-linked immunosorbent assay; free testosterone was calculated from a mathematical model using sex hormone binding globulin, albumin, and total testosterone (quantified by liquid chromatography-mass spectrometry); A4 and DHEA were quantified by liquid chromatography-mass spectrometry; and serum insulin, DHEA-S, FSH, LH, prolactin, thyroid-stimulating hormone, serum hCG, and progesterone were determined by immunoassay. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated from the fasting blood glucose and serum insulin (HOMA-IR=fasting insulin x fasting glucose / 405).50 
Assessment of Anxiety and Depression
All participants were provided unique website links to complete the BAI and BDI-II before the 3-month intervention and within 1 week of the completion of the intervention period. These surveys have documented validity, and reviews of multiple studies have indicated high reliability.51,52 Surveys were automatically scored online. The BAI scores were reported on a range of 0 to 63, with total scores interpreted as follows: 0 to 7, minimal anxiety; 8 to 15, mild anxiety; 16 to 25, moderate anxiety; and 26 to 63, severe anxiety. The BDI-II scores were reported on a range of 0 to 63, with total scores interpreted as follows: 0 to 13, minimal depression; 14 to 19, mild depression; 20 to 28, moderate depression; and 29 to 63, severe depression. 
Mindfulness Training
All women in the mindful yoga intervention group participated in a 3-hour workshop on the principles and practice of mindfulness, as this was an integral component of the mindful yoga group practice. Topics covered included the Benson breathing exercise, slow walking meditation, positive self-talk, tapping, guided imagery, and appreciative inquiry. The workshop was conducted by 2 registered nurses, each with over 40 years’ experience in women's health, as well as certification in specialties involving meditation and mindfulness practice (certified hypnotist instructors and appreciative inquiry practitioner). The workshop was also attended by the yoga instructor for the intervention group, who incorporated elements of mindfulness throughout the 3-month mindful yoga class, including breathing exercises and guided imagery. 
Mindful Yoga Intervention
Women in the mindful yoga intervention group participated in a 3-times-per-week group class at the Lake Erie College of Osteopathic Medicine Wellness Center with the same experienced and certified yoga instructor and therapist from February 2017 until May 2017 (3 months). Each class was 1 hour and followed a curriculum that began with body awareness through a mental body scan, moving into a practice that included pranayama exercises (3-part yogic breath: ujjayi breath, alternate nostril breathing, and breath of fire), vinyasa flow yoga, restorative yoga asanas, and concluded with meditation that incorporated guided imagery of healing energy and mindful “I am” statements. 
Participants in the control group were instructed to complete the initial and 3-month measurements and asked not to change any aspects of their daily routine (eg, no changes to diet, activity level, or therapies). Participants reported no changes to their daily routine. 
Statistical Analysis
Power analysis was conducted with the Statistical Decision Tree Power Calculator (QFAB Bioinformatics) to determine the sample size needed to detect a Pearson correlation coefficient of 0.6 with a power of at least .80, with a significance level of .05 (n=8 per group). GraphPad Prism 7.03 software was used for data analysis. Mean values of initial parameters (age, BMI, waist-to-hip ratio) for women in each group were analyzed with unpaired t tests to ensure that the groups were comparable. Paired t tests (for normally distributed data) or Wilcoxon matched-pair signed rank tests (for data that were not normally distributed) were used to compare participants' preintervention measurements (0 months, January 2017) with their postintervention measurements (3 months, May 2017). Repeated-measures analysis of variance (for normally distributed data) or Friedman test (for data that were not normally distributed) with the post hoc Tukey test was used to determine whether there were any significant differences between participants' initial (January 2017), post intervention (May 2017), and subsequent no intervention for 3 months (6 months, August 2017) measurements. Significance was set at P<.05, with P values between .05 and .10 considered trending. 
Results
During the intervention period, 2 of the 11 participants assigned to the control group did not complete initial measurements, resulting in 9 participants for data analysis. In the mindful yoga group, 2 of the 20 participants did not complete the initial measurements, 1 participant completed initial measurements but did not attend any classes or complete the 3-month measurements, 1 participant stopped attending yoga classes after 6 weeks and did not return for 3-month measurements, and 3 participants did not complete the 3-month measurements, resulting in 13 participants for data analysis. 
Participant Demographics
Table 1 shows the mean values for participant demographics for the initial group assignments, with no significant difference in participant age, BMI, waist-to-hip ratio, or menstrual irregularity. 
Table 1.
Demographics for Participants Completing Initial Measurements
Characteristic No intervention (n=9) Yoga intervention (n=18) P valuea
Participants at study start, n 9 18
Age, y, mean (SD) 31.2 (2.3) 30.9 (1.2) .968
BMI, mean (SD) (reference range,18.5-24.9) 35.4 (3.3) 35.1 (1.5) .948
Waist-to-hip ratio, mean (SD) (reference <0.85) 0.8003 (0.020) 0.8509 (0.014) .056
Mean menstrual cycle length, d (reference range, 25-34 d) >35 >35

aStatistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviation: BMI, body mass index.

Table 1.
Demographics for Participants Completing Initial Measurements
Characteristic No intervention (n=9) Yoga intervention (n=18) P valuea
Participants at study start, n 9 18
Age, y, mean (SD) 31.2 (2.3) 30.9 (1.2) .968
BMI, mean (SD) (reference range,18.5-24.9) 35.4 (3.3) 35.1 (1.5) .948
Waist-to-hip ratio, mean (SD) (reference <0.85) 0.8003 (0.020) 0.8509 (0.014) .056
Mean menstrual cycle length, d (reference range, 25-34 d) >35 >35

aStatistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviation: BMI, body mass index.

×
Androgen Levels
Participants who regularly attended the mindful yoga class and participants in the no intervention (control) group had their blood work and clinical assessments repeated within 2 weeks of the final class (3 months); these values were compared with their initial values (0 months) by paired comparison statistical testing to compare individual participant's pre- and postintervention values (Table 2). While no improvements were observed in androgen levels for participants in the control group, there was a significant decrease in free testosterone for participants in the mindful yoga group (5.96 vs 4.24 pg/mL; P=.0413), and DHEA levels also trended lower (359.7 vs 316.6 ng/mL; P=.0574). No significant improvements were noted in either group for DHEA-S, A4, or mFG score for hirsutism. Some participants reported an improvement in their acne, as well as a shorter menstrual cycle length after the yoga intervention (data not shown). 
Table 2.
Participant Parameters Before and After the 3-Month Intervention (N=13)a,b
Test Control (0 mo) (n=9) Control (3 mo) (n=9) P valueb Yoga (0 mo) (n=13) Yoga (3 mo) (n=13) P Valueb
Free T, pg/mL, (reference range, 0.2-0.5 pg/mL) 7.39 (1.61) 7.36 (1.29) .967 5.96 (1.2) 4.24 (0.6) .0413
DHEA ng/dL (reference range, 102-1185) 382.7 (56-713) 368.3 (65-541) .742 359.7 (109-892) 316.6 (114-914) .0574  
DHEAS (µg/dL) (reference range, 45-320) 197.4 (30.7) 224.4 (34.1) .0038 177.2 (22.5) 167.7 (19.1) .501
A4 (ng/dL) (reference range, 30-250) 209.2 (56.0) 246.2 (45.9) .147 175.8 (22.1) 158.3 (16.3) .224
mFG score (>6) 4.0 (0.6) 4 (0.6) .999 3.3 (0.6) 3.3 (0.6) .950
Fasting BG, mg/dL, (reference range, 65-99) 89.2 (4.5) 92.1 (2.7) .403 87.9 (1.9) 86.3 (1.9) .387
Fasting insulin, µIU/mL (reference range, <23) 14.8 (3.9) 12.7 (2.7) .328 mean (range), 11.0 (2-33) mean (range), 10.0 (2-47) .824
HOMA-IR (reference range, 0.5-1.4) 3.48 (1.02) 3.00 (0.66) .382 mean (range), 2.3 (0.4-0.7) mean (range), 2 (0.4-11.3) .693
Adiponectin, µg/mL, (reference range, 5-28) 8.1 (1.3) 9.0 (1.7) .252 10.6 (1.1) 8.8 (1.2) .0045
BMI (reference range, 18.5-24.9) 35.4 (3.3) 35.6 (3.3) .403 35.0 (1.9) 34.7 (2.0) .375
Waist-to-hip ratio 0.8003 (0.020) 0.8114 (0.020) .344 0.8449 (0.017) 0.8319 (0.015) .319
BAI score 12.0 (2.9) 10.9 (2.2) .633 14.4 (3.0) 11.3 (2.1) .0365
BDI-II score 18.0 (2.1) 12.0 (1.7) .06 16.0 (2.8) 7.25 (2.1) <.0001

aData are given as mean (SD) unless otherwise indicated.

bP value was used to evaluate endocrine, metabolic, and psychologic differences between the group that completed regular yoga intervention and the group that did not (control). Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: A4, androstenedione; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory BG, blood glucose; BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; T, testosterone; mFG, modified Ferriman-Gallwey.

Table 2.
Participant Parameters Before and After the 3-Month Intervention (N=13)a,b
Test Control (0 mo) (n=9) Control (3 mo) (n=9) P valueb Yoga (0 mo) (n=13) Yoga (3 mo) (n=13) P Valueb
Free T, pg/mL, (reference range, 0.2-0.5 pg/mL) 7.39 (1.61) 7.36 (1.29) .967 5.96 (1.2) 4.24 (0.6) .0413
DHEA ng/dL (reference range, 102-1185) 382.7 (56-713) 368.3 (65-541) .742 359.7 (109-892) 316.6 (114-914) .0574  
DHEAS (µg/dL) (reference range, 45-320) 197.4 (30.7) 224.4 (34.1) .0038 177.2 (22.5) 167.7 (19.1) .501
A4 (ng/dL) (reference range, 30-250) 209.2 (56.0) 246.2 (45.9) .147 175.8 (22.1) 158.3 (16.3) .224
mFG score (>6) 4.0 (0.6) 4 (0.6) .999 3.3 (0.6) 3.3 (0.6) .950
Fasting BG, mg/dL, (reference range, 65-99) 89.2 (4.5) 92.1 (2.7) .403 87.9 (1.9) 86.3 (1.9) .387
Fasting insulin, µIU/mL (reference range, <23) 14.8 (3.9) 12.7 (2.7) .328 mean (range), 11.0 (2-33) mean (range), 10.0 (2-47) .824
HOMA-IR (reference range, 0.5-1.4) 3.48 (1.02) 3.00 (0.66) .382 mean (range), 2.3 (0.4-0.7) mean (range), 2 (0.4-11.3) .693
Adiponectin, µg/mL, (reference range, 5-28) 8.1 (1.3) 9.0 (1.7) .252 10.6 (1.1) 8.8 (1.2) .0045
BMI (reference range, 18.5-24.9) 35.4 (3.3) 35.6 (3.3) .403 35.0 (1.9) 34.7 (2.0) .375
Waist-to-hip ratio 0.8003 (0.020) 0.8114 (0.020) .344 0.8449 (0.017) 0.8319 (0.015) .319
BAI score 12.0 (2.9) 10.9 (2.2) .633 14.4 (3.0) 11.3 (2.1) .0365
BDI-II score 18.0 (2.1) 12.0 (1.7) .06 16.0 (2.8) 7.25 (2.1) <.0001

aData are given as mean (SD) unless otherwise indicated.

bP value was used to evaluate endocrine, metabolic, and psychologic differences between the group that completed regular yoga intervention and the group that did not (control). Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: A4, androstenedione; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory BG, blood glucose; BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; T, testosterone; mFG, modified Ferriman-Gallwey.

×
Metabolic Parameters
Cardiometabolic parameters for participants before- and after intervention are shown in Table 2. No significant changes were noted in either group for fasting blood glucose, insulin, homeostatic model assessment of insulin resistance (HOMA-IR), BMI, or waist-to-hip ratio. However, there was a significant decrease in adiponectin in the mindful yoga group participants (10.6 vs 8.8 μg/mL; P =.0045). 
Anxiety and Depression
Scores for anxiety (14.4 vs 11.3; P=.0365) and depression (16.0 vs 7.25; P<.001) significantly improved after the 3-month mindful yoga intervention (Table 2). In the control group, scores for depression also trended lower (18.0 vs 12.0; P=.06). 
Free Testosterone
To determine whether improvements in serum free testosterone or DHEA level or the change in adiponectin would persist without continued participation in mindful yoga, we reassessed these parameters for women in the mindful yoga group who did not continue practicing yoga for 3 months after the completion of the intervention (6-month follow-up). Participants who reported that they practiced yoga during this postintervention period were not included in this 6-month follow-up. For the participants who completed this final assessment (9 of the 13 who completed the 3-month mindful yoga intervention), we found that free testosterone levels remained similar to the improved levels observed after the 3-month mindful yoga intervention (Table 3), with significant improvement after yoga intervention (7.1 vs 4.3 vs 4.9; P=.0201), although the difference between the 0 months and 6 months values trended toward but did not reach significance (P=.06). No significant difference was found in DHEA levels, although the median value did remain lower compared with the initial value for this group of 9 participants (277 vs 205 vs 216). The mean adiponectin level did increase compared with the postintervention value, but did not reach the level initially observed in this group of 9 participants (10.3 vs 8.2 vs 9.1; P=.0508). 
Table 3.
Persistent Improvement in Serum Testosterone Level After Yoga Intervention
Test Yoga (0 mo) (n=9) Yoga (3 mo) (n=9) Yoga (6 mo) (n=9) P value*
Free T, pg/mL (reference range, 0.2-5.0 pg/mL) 7.1 (4.4) 4.3 (2.2) 4.9 (2.6) .0201
DHEA, ng/dL (reference range, 102-1185 ng/dL) 277 (109-892) 205 (114-914) 216 (113-481) .569
Adiponectin, µg/mL, mean (SD) (reference range, 5-28 mg/mL) 10.3 (4.2) 8.2 (3.9) 9.1 (4.9) .0508

*Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: BMI, body mass index; DHEA, dehydroepiandrosterone; T, testosterone.

Table 3.
Persistent Improvement in Serum Testosterone Level After Yoga Intervention
Test Yoga (0 mo) (n=9) Yoga (3 mo) (n=9) Yoga (6 mo) (n=9) P value*
Free T, pg/mL (reference range, 0.2-5.0 pg/mL) 7.1 (4.4) 4.3 (2.2) 4.9 (2.6) .0201
DHEA, ng/dL (reference range, 102-1185 ng/dL) 277 (109-892) 205 (114-914) 216 (113-481) .569
Adiponectin, µg/mL, mean (SD) (reference range, 5-28 mg/mL) 10.3 (4.2) 8.2 (3.9) 9.1 (4.9) .0508

*Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: BMI, body mass index; DHEA, dehydroepiandrosterone; T, testosterone.

×
Discussion
We found that thrice-weekly yoga practice significantly improved free testosterone levels, a major criterion used for the diagnosis of PCOS, with DHEA levels trending lower as well. Furthermore, these benefits were observed without daily yoga practice, but rather with a more feasible 3-times-per-week practice. Scores for anxiety and depression were also improved with this intervention. 
Mindful Yoga as Therapy for PCOS
Women with PCOS have expressed a desire for more natural and holistic therapies to manage their symptoms.26,27 Unlike some other forms of exercise, yoga is very accessible to a variety of individuals in that it can be practiced by people of all ages and body types, does not require a specific fitness or skill level, does not require equipment, and may be performed in a studio with an instructor or at home. Yoga practice has become increasingly popular as a complementary health approach,53 and it has been reported to be useful in patients with a variety of conditions.36-40 In line with osteopathic philosophy, yoga practice embraces the relationship between mind, body, and spirit, and produces measurable physiologic effects. Because of its accessibility and success in helping with other chronic disorders as well as previous reports demonstrating its utility in adolescents with PCOS,44,45 mindful yoga has potential as a complementary or alternative therapy option for women with PCOS. Our findings support the effectiveness of this type of therapy for this population. 
Mindful Yoga in Women With Established PCOS
The women in our study had an mean age of 31 years (range, 23-42 years), indicating that their PCOS diagnosis was established and their health potentially affected by the disorder for a decade or more.19 Women in this study group exhibited aspects of reproductive dysfunction, such as menstrual cycles longer than 5 days and difficulty conceiving, as well as metabolic dysfunction, such as elevated HOMA-IR (an indicator of insulin resistance), BMI, and waist-to-hip ratio. Despite having PCOS for many years and experiencing some of the associated reproductive and metabolic dysfunction, our results indicate that women with established PCOS and metabolic dysfunction can benefit from regular mindful yoga practice, with potential improvement in androgen profile. That these results can be achieved with a feasible thrice-weekly practice rather than daily practice is an additional benefit. 
A4 and DHEA Levels
Diagnosis of PCOS often includes hyperandrogenism, which may be clinical or biochemical. Biochemical hyperandrogenism is usually assessed by serum free testosterone levels, although the weak androgens DHEA and A4 may also be elevated in women with PCOS.54 Androstenedione has recently been reported to correlate with hirsutism and risk for metabolic disease in women with PCOS, sometimes even in the presence of normal testosterone levels.55 Furthermore, A4 may be associated with a more severe PCOS phenotype, including elevated LH, LH:FSH ratio, testosterone, DHEA-S, and free androgen index, as well as increased ovarian volume and greater mean number of follicles in hyperandrogenic women with PCOS.56 The average initial A4 concentration in our study participants was at the high end but still within normal range, with some participants exhibiting normal A4 levels, which may explain why the decrease did not reach significance with our small sample size. Similarly, the DHEA levels in our study participants were within normal limits, with a trending decrease after intervention. 
Cardiometabolic Measurements
While the 3-month mindful yoga intervention improved the androgen profile of women with PCOS, it did not result in a significant improvement in the metabolic parameters assessed in this study. Similar to the findings reported by Nidhi et al,44 there was no significant change in BMI or WHR in women completing the 3-month intervention. However, in contrast with their findings, we did not find improvements in fasting insulin, glucose, or HOMA-IR. This may be because their study employed daily yoga for 1 hour for 12 weeks, which is a more rigorous program than our thrice-weekly class. The difference may also be attributed to the participant demographics; our study included women with a history of PCOS and measurements reflective of chronic metabolic dysfunction, including an average BMI of 35 and a higher HOMA-IR score, whereas Nidhi et al44 included female adolescents with an average BMI of 20.3 and a lower HOMA-IR (near 3.0 in the current study vs 1.7 in their population). With a population of women who have had PCOS for a decade or longer, the effects of the underlying pathophysiology and the associated metabolic dysfunction may be more pervasive, which could explain the lack of significant improvement in metabolic parameters for the women in our study. By contrast, a population of young, lean women with PCOS might be more pliable with respect to their metabolic parameters, as observed in the study by Nidhi et al.44 If this is the case, it underscores the importance of implementing this type of therapy as soon as possible after diagnosis in order to achieve maximum benefits, both in terms of endocrine as well as metabolic health. 
Adiponectin Levels
Surprisingly, there was a significant decrease in adiponectin levels with completion of the mindful yoga intervention. Adiponectin is an adipose-derived hormone that is associated with insulin sensitivity and anti-inflammatory effects.57 Most reports indicated that higher adiponectin levels were beneficial, whereas lower adiponectin levels have been associated with insulin resistance, type 2 diabetes, metabolic syndrome, and PCOS.57-60 In the current study, it is unclear why adiponectin levels would decrease after the intervention. One possibility is that there was a change in the ratio of high molecular weight adiponectin to total adiponectin. This ratio is reported to better predict insulin resistance, as a decrease correlates with greater insulin resistance.61 The immunoassay used in our study was not able to distinguish between the different molecular weight forms, but it is possible that there was a change in the ratio of high molecular weight to total adiponectin despite lower total adiponectin. Another possibility is that there could have been an increase in adiponectin receptor expression in these women, potentially improving responsiveness to adiponectin but resulting in a decrease in circulating adiponectin levels. Further investigation in a larger study population could help to determine whether lower adiponectin levels are consistently found in association with yoga practice and help to determine the mechanism underlying the decrease. 
Psychological Improvements
Women completing the mindful yoga intervention experienced significant improvements in both anxiety and depression. This may be partially attributed to seasonal changes, as a trend toward lower depression scores was also seen in the control group. It is worth noting that the women in the mindful yoga intervention group reported a sense of community by participating in this study together, which itself could result in improved stress levels and potentially provide therapeutic benefit. In addition, incorporation of mindfulness practice in everyday life may have also contributed to the observed therapeutic benefit in this group, particularly with respect to anxiety and depression. 
Limitations
One limitation of this study was the small sample size for each group, which could affect the statistical significance of our findings. The participants in this study were of varying BMIs and ages; in addition to larger randomized controlled studies, future studies could also focus on determining whether this type of yoga practice has a greater impact on women in a specific age group or within a specific BMI range. It is noteworthy that the intervention group used mindfulness as part of their group yoga practice, and they may have incorporated aspects of the mindfulness practice in their daily lives; beyond the yoga practice itself, this factor also may have contributed to the therapeutic benefits observed in this study. Despite these limitations, the results suggest that mindful yoga practice can provide therapeutic benefit to women with PCOS. Furthermore, the improvements in androgen levels are a promising finding, as these hormones may contribute to the pathogenesis of the disorder itself. 
Conclusion
We found that thrice-weekly mindful yoga practice improved serum androgen levels, a hallmark feature of PCOS, in women with PCOS. This improvement was observed in the absence of weight loss, and may persist even if there is a lapse in yoga practice. These findings suggest that regular mindful yoga can be a useful complementary therapeutic option, in conjunction with improved diet, to lead to better health in women with PCOS. 
Acknowledgments
We thank Karen Ducato, C-IAYT, E-RYT500, for her guidance and expertise in leading the group mindful yoga classes for the study. We also thank Jan Hendryx, DO, and Sarah Davis, DO, for their helpful discussions and feedback on the data. 
References
Franks S. Polycystic ovary syndrome. N Engl J Med. . 1995;333(13):853-861. [CrossRef] [PubMed]
March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. . 2010;25(2):544-551. [CrossRef] [PubMed]
Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. . 2011;7(4):219-231. [CrossRef] [PubMed]
Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage. J Clin Endocrinol Metab. . 2015;100(3):911-919. [CrossRef] [PubMed]
Berger JJ, Bates GW. Optimal management of subfertility in polycystic ovary syndrome. Int J Womens Health. . 2014;6:613-621. [PubMed]
Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine. . 2006;30(1):45-53. [CrossRef] [PubMed]
Carmina E. Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res. . 2013;40:40-50. [CrossRef] [PubMed]
Spritzer PM, Lecke SB, Satler F, Morsch DM. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. . 2015;149(5):R219-227. [CrossRef] [PubMed]
Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. . 1986;62(5):904-910. [CrossRef] [PubMed]
Lu C, Cardoso RC, Puttabyatappa M, Padmanabhan V. Developmental programming: prenatal testosterone excess and insulin signaling disruptions in female sheep. Biol Reprod. . 2016;94(5):113. [CrossRef] [PubMed]
Mauras N, Welch S, Rini A, Haymond MW. Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: a metabolic study. J Clin Endocrinol Metab. . 1998;83(6):1900-1905. [PubMed]
Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine. . 2006;30(1):13-17. [CrossRef] [PubMed]
Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf. ). 1994;41(4):473-481. [CrossRef] [PubMed]
Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. . 2009;92(6):1966-1982. [CrossRef] [PubMed]
Morciano A, Romani F, Sagnella F, et al. Assessment of insulin resistance in lean women with polycystic ovary syndrome. Fertil Steril. . 2014;102(1):250-256.e253. [CrossRef] [PubMed]
Pasquali R, Gambineri A. Role of changes in dietary habits in polycystic ovary syndrome. Reprod Biomed Online. . 2004;8(4):431-439. [CrossRef] [PubMed]
Berni TR, Morgan CL, Berni ER, Rees DA. Polycystic ovary syndrome is associated with adverse mental health and neurodevelopmental outcomes. J Clin Endocrinol Metab. 2018;103(6):2116-2125. doi: 10.1210/jc.2017-02667 [CrossRef] [PubMed]
Amini L, Valian K, Sdeghi Avvalshahr H, Montaeri A. Self-confidence in women with and without polycystic ovary syndrome. J Family Reprod Health. 2014;8(3):113-116. [PubMed]
Welt CK, Carmina E. Clinical review: lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab. 2013;98(12):4629-4638. [CrossRef] [PubMed]
Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012;30(6):496-506. [CrossRef] [PubMed]
Marzouk TM, Sayed Ahmed WA. Effect of dietary weight loss on menstrual regularity in obese young adult women with polycystic ovary syndrome. J Pediatr Adolesc Gynecol. 2015;28(6):457-461. [CrossRef] [PubMed]
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1. Endocr Pract. 2015;21(11):1291-1300. [CrossRef] [PubMed]
Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 2. Endocr Pract. 2015;21(12):1415-1426. [CrossRef] [PubMed]
McCully KS. Homocystine, atherosclerosis and thrombosis: implications for oral contraceptive users. Am J Clin Nutr. 1975;28(5):542-549. [CrossRef] [PubMed]
Miller K. Birth control and cancer: which methods raise, lower risk. American Cancer Society website. https://www.cancer.org/latest-news/birth-control-cancer-which-methods-raise-lower-risk.html. Published 2016. Accessed July 1, 2019, 2019.
Arentz S, Smith CA, Abbott JA, Bensoussan A. A survey of the use of complementary medicine by a self-selected community group of Australian women with polycystic ovary syndrome. BMC Complement Altern Med. 2014;14:472.
Sills ES, Perloe M, Tucker MJ, Kaplan CR, Genton MG, Schattman GL. Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports. BMC Womens Health. 2001;1(1):3. [CrossRef] [PubMed]
Domecq JP, Prutsky G, Mullan RJ, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4655-4663. [CrossRef] [PubMed]
Wright CE, Zborowski JV, Talbott EO, McHugh-Pemu K, Youk A. Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2004;28(8):1026-1032. [CrossRef] [PubMed]
Arentz S, Abbott JA, Smith CA, Bensoussan A. Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement Altern Med. 2014;14:511.
Kuang H, Li Y, Wu X, et al. Acupuncture and clomiphene citrate for live birth in polycystic ovary syndrome: study design of a randomized controlled trial. Evid Based Complement Alternat Med. 2013;2013:527303.
Mannerås L, Cajander S, Lönn M, Stener-Victorin E. Acupuncture and exercise restore adipose tissue expression of sympathetic markers and improve ovarian morphology in rats with dihydrotestosterone-induced PCOS. Am J Physiol Regul Integr Comp Physiol. 2009;296(4):R1124-R1131. [CrossRef] [PubMed]
Hoeger KM. Exercise therapy in polycystic ovary syndrome. Semin Reprod Med. 2008;26(1):93-100. [CrossRef] [PubMed]
Miri M, Karimi Jashni H, Alipour F. Effect of exercise intensity on weight changes and sexual hormones (androstenedione and free testosterone) in female rats with estradiol valerate-induced PCOS. J Ovarian Res. 2014;7:37.
Sá JC, Costa EC, da Silva E, et al. Aerobic exercise improves cardiac autonomic modulation in women with polycystic ovary syndrome. Int J Cardiol. 2016;202:356-361.
Chang DG, Holt JA, Sklar M, Groessl EJ. Yoga as a treatment for chronic low back pain: a systematic review of the literature. J Orthop Rheumatol. 2016;3(1):1-8. [PubMed]
Cramer H, Posadzki P, Dobos G, Langhorst J. Yoga for asthma: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2014;112(6):503-510.e505. [CrossRef] [PubMed]
Cramer H. The efficacy and safety of yoga in managing hypertension. Exp Clin Endocrinol Diabetes. 2016;124(2):65-70. [PubMed]
Pascoe MC, Thompson DR, Ski CF. Yoga, mindfulness-based stress reduction and stress-related physiological measures: a meta-analysis. Psychoneuroendocrinology. 2017;86:152-168. [CrossRef] [PubMed]
Rogers KA, MacDonald M. Therapeutic Yoga: Symptom Management for Multiple Sclerosis. J Altern Complement Med. 2015;21(11):655-659. [CrossRef] [PubMed]
Singh VP, Khandelwal B, Sherpa NT. Psycho-neuro-endocrine-immune mechanisms of action of yoga in type II diabetes. Anc Sci Life. 2015;35(1):12-17. [CrossRef] [PubMed]
Naveen GH, Varambally S, Thirthalli J, Rao M, Christopher R, Gangadhar BN. Serum cortisol and BDNF in patients with major depression-effect of yoga. Int Rev Psychiatry. 2016;28(3):273-278. [CrossRef] [PubMed]
Gallegos AM, Hoerger M, Talbot NL, et al. Toward identifying the effects of the specific components of mindfulness-based stress reduction on biologic and emotional outcomes among older adults. J Altern Complement Med. 2013;19(10):787-792. [CrossRef] [PubMed]
Nidhi R, Padmalatha V, Nagarathna R, Ram A. Effect of a yoga program on glucose metabolism and blood lipid levels in adolescent girls with polycystic ovary syndrome. Int J Gynaecol Obstet. 2012;118(1):37-41. [CrossRef] [PubMed]
Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Effects of a holistic yoga program on endocrine parameters in adolescents with polycystic ovarian syndrome: a randomized controlled trial. J Altern Complement Med. 2013;19(2):153-160. [CrossRef] [PubMed]
Davis SE, Hendryx J, Menezes C, et al Weekly osteopathic manipulative treatment to improve measures of sympathetic tone in women with polycystic ovary syndrome: a randomized, controlled pilot study. J Am Osteopath Assoc. 2020;120(5):310-321. doi: 10.7556/jaoa.2020.051
Revised Group REA-SPCW. 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
Cramer H, Haller H, Dobos G, Lauche R. A systematic review and meta-analysis estimating the expected dropout rates in randomized controlled trials on yoga interventions. Evid Based Complement Alternat Med. 2016;2016:5859729.
Bhatt A. Protocol deviation and violation. Perspect Clin Res. 2012;3(3):117. [CrossRef] [PubMed]
Majid H, Masood Q, Khan AH. Homeostatic model assessment for insulin resistance (HOMA-IR): a better marker for evaluating insulin resistance than fasting insulin in women with polycystic ovarian syndrome. J Coll Physicians Surg Pak. 2017 Mar;27(3):123-126. [PubMed]
Wang YP, Gorenstein C. Assessment of depression in medical patients: a systematic review of the utility of the Beck Depression Inventory-II. Clinics (Sao Paulo. ). 2013;68(9):1274-1287. [CrossRef] [PubMed]
Kabacoff RI, Segal DL, Hersen M, Van Hasselt VB. Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State-Trait Anxiety Inventory with older adult psychiatric outpatients. J Anxiety Disord. 1997;11(1):33-47. [CrossRef] [PubMed]
Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl Health Stat Report. 2015(79):1-16.
Pasquali R, Zanotti L, Fanelli F, et al. Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. J Clin Endocrinol Metab. 2016;101(5):2013-2022. [CrossRef] [PubMed]
O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab. 2014;99(3):1027-1036. [CrossRef] [PubMed]
Georgopoulos NA, Papadakis E, Armeni AK, Katsikis I, Roupas ND, Panidis D. Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS). Hormones (Athens. ). 2014;13(2):213-221. [CrossRef] [PubMed]
Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792. [CrossRef] [PubMed]
Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20(6):1595-1599. [CrossRef] [PubMed]
Kishida K, Funahashi T, Shimomura I. Adiponectin as a routine clinical biomarker. Best Pract Res Clin Endocrinol Metab. 2014;28(1):119-130. [CrossRef] [PubMed]
Mirza SS, Shafique K, Shaikh AR, Khan NA, Anwar Qureshi M. Association between circulating adiponectin levels and polycystic ovarian syndrome. J Ovarian Res. 2014;7:18.
Dadson K, Liu Y, Sweeney G. Adiponectin action: a combination of endocrine and autocrine/paracrine effects. Front Endocrinol (Lausanne. ). 2011;2:62.
Figure.
Study design overview and timeline. Women with polycystic ovary syndrome (PCOS) were recruited from the Erie, PA, area using media advertising. After informed consent to participate in the study and release medical records, eligibility was determined according to inclusion and exclusion criteria, using Rotterdam criteria, and a questionnaire. Participants (N=13) were randomly assigned to the no intervention (control) or mindful yoga intervention group. Thirty-one participants were enrolled in the study, and 22 completed the 3-month intervention period and postintervention measurements. An additional 14 participants were included in a separate arm of the study assessing osteopathic manipulative treatment (OMT) for sympathetic tone in women with PCOS.46
Figure.
Study design overview and timeline. Women with polycystic ovary syndrome (PCOS) were recruited from the Erie, PA, area using media advertising. After informed consent to participate in the study and release medical records, eligibility was determined according to inclusion and exclusion criteria, using Rotterdam criteria, and a questionnaire. Participants (N=13) were randomly assigned to the no intervention (control) or mindful yoga intervention group. Thirty-one participants were enrolled in the study, and 22 completed the 3-month intervention period and postintervention measurements. An additional 14 participants were included in a separate arm of the study assessing osteopathic manipulative treatment (OMT) for sympathetic tone in women with PCOS.46
Table 1.
Demographics for Participants Completing Initial Measurements
Characteristic No intervention (n=9) Yoga intervention (n=18) P valuea
Participants at study start, n 9 18
Age, y, mean (SD) 31.2 (2.3) 30.9 (1.2) .968
BMI, mean (SD) (reference range,18.5-24.9) 35.4 (3.3) 35.1 (1.5) .948
Waist-to-hip ratio, mean (SD) (reference <0.85) 0.8003 (0.020) 0.8509 (0.014) .056
Mean menstrual cycle length, d (reference range, 25-34 d) >35 >35

aStatistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviation: BMI, body mass index.

Table 1.
Demographics for Participants Completing Initial Measurements
Characteristic No intervention (n=9) Yoga intervention (n=18) P valuea
Participants at study start, n 9 18
Age, y, mean (SD) 31.2 (2.3) 30.9 (1.2) .968
BMI, mean (SD) (reference range,18.5-24.9) 35.4 (3.3) 35.1 (1.5) .948
Waist-to-hip ratio, mean (SD) (reference <0.85) 0.8003 (0.020) 0.8509 (0.014) .056
Mean menstrual cycle length, d (reference range, 25-34 d) >35 >35

aStatistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviation: BMI, body mass index.

×
Table 2.
Participant Parameters Before and After the 3-Month Intervention (N=13)a,b
Test Control (0 mo) (n=9) Control (3 mo) (n=9) P valueb Yoga (0 mo) (n=13) Yoga (3 mo) (n=13) P Valueb
Free T, pg/mL, (reference range, 0.2-0.5 pg/mL) 7.39 (1.61) 7.36 (1.29) .967 5.96 (1.2) 4.24 (0.6) .0413
DHEA ng/dL (reference range, 102-1185) 382.7 (56-713) 368.3 (65-541) .742 359.7 (109-892) 316.6 (114-914) .0574  
DHEAS (µg/dL) (reference range, 45-320) 197.4 (30.7) 224.4 (34.1) .0038 177.2 (22.5) 167.7 (19.1) .501
A4 (ng/dL) (reference range, 30-250) 209.2 (56.0) 246.2 (45.9) .147 175.8 (22.1) 158.3 (16.3) .224
mFG score (>6) 4.0 (0.6) 4 (0.6) .999 3.3 (0.6) 3.3 (0.6) .950
Fasting BG, mg/dL, (reference range, 65-99) 89.2 (4.5) 92.1 (2.7) .403 87.9 (1.9) 86.3 (1.9) .387
Fasting insulin, µIU/mL (reference range, <23) 14.8 (3.9) 12.7 (2.7) .328 mean (range), 11.0 (2-33) mean (range), 10.0 (2-47) .824
HOMA-IR (reference range, 0.5-1.4) 3.48 (1.02) 3.00 (0.66) .382 mean (range), 2.3 (0.4-0.7) mean (range), 2 (0.4-11.3) .693
Adiponectin, µg/mL, (reference range, 5-28) 8.1 (1.3) 9.0 (1.7) .252 10.6 (1.1) 8.8 (1.2) .0045
BMI (reference range, 18.5-24.9) 35.4 (3.3) 35.6 (3.3) .403 35.0 (1.9) 34.7 (2.0) .375
Waist-to-hip ratio 0.8003 (0.020) 0.8114 (0.020) .344 0.8449 (0.017) 0.8319 (0.015) .319
BAI score 12.0 (2.9) 10.9 (2.2) .633 14.4 (3.0) 11.3 (2.1) .0365
BDI-II score 18.0 (2.1) 12.0 (1.7) .06 16.0 (2.8) 7.25 (2.1) <.0001

aData are given as mean (SD) unless otherwise indicated.

bP value was used to evaluate endocrine, metabolic, and psychologic differences between the group that completed regular yoga intervention and the group that did not (control). Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: A4, androstenedione; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory BG, blood glucose; BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; T, testosterone; mFG, modified Ferriman-Gallwey.

Table 2.
Participant Parameters Before and After the 3-Month Intervention (N=13)a,b
Test Control (0 mo) (n=9) Control (3 mo) (n=9) P valueb Yoga (0 mo) (n=13) Yoga (3 mo) (n=13) P Valueb
Free T, pg/mL, (reference range, 0.2-0.5 pg/mL) 7.39 (1.61) 7.36 (1.29) .967 5.96 (1.2) 4.24 (0.6) .0413
DHEA ng/dL (reference range, 102-1185) 382.7 (56-713) 368.3 (65-541) .742 359.7 (109-892) 316.6 (114-914) .0574  
DHEAS (µg/dL) (reference range, 45-320) 197.4 (30.7) 224.4 (34.1) .0038 177.2 (22.5) 167.7 (19.1) .501
A4 (ng/dL) (reference range, 30-250) 209.2 (56.0) 246.2 (45.9) .147 175.8 (22.1) 158.3 (16.3) .224
mFG score (>6) 4.0 (0.6) 4 (0.6) .999 3.3 (0.6) 3.3 (0.6) .950
Fasting BG, mg/dL, (reference range, 65-99) 89.2 (4.5) 92.1 (2.7) .403 87.9 (1.9) 86.3 (1.9) .387
Fasting insulin, µIU/mL (reference range, <23) 14.8 (3.9) 12.7 (2.7) .328 mean (range), 11.0 (2-33) mean (range), 10.0 (2-47) .824
HOMA-IR (reference range, 0.5-1.4) 3.48 (1.02) 3.00 (0.66) .382 mean (range), 2.3 (0.4-0.7) mean (range), 2 (0.4-11.3) .693
Adiponectin, µg/mL, (reference range, 5-28) 8.1 (1.3) 9.0 (1.7) .252 10.6 (1.1) 8.8 (1.2) .0045
BMI (reference range, 18.5-24.9) 35.4 (3.3) 35.6 (3.3) .403 35.0 (1.9) 34.7 (2.0) .375
Waist-to-hip ratio 0.8003 (0.020) 0.8114 (0.020) .344 0.8449 (0.017) 0.8319 (0.015) .319
BAI score 12.0 (2.9) 10.9 (2.2) .633 14.4 (3.0) 11.3 (2.1) .0365
BDI-II score 18.0 (2.1) 12.0 (1.7) .06 16.0 (2.8) 7.25 (2.1) <.0001

aData are given as mean (SD) unless otherwise indicated.

bP value was used to evaluate endocrine, metabolic, and psychologic differences between the group that completed regular yoga intervention and the group that did not (control). Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: A4, androstenedione; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory BG, blood glucose; BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; T, testosterone; mFG, modified Ferriman-Gallwey.

×
Table 3.
Persistent Improvement in Serum Testosterone Level After Yoga Intervention
Test Yoga (0 mo) (n=9) Yoga (3 mo) (n=9) Yoga (6 mo) (n=9) P value*
Free T, pg/mL (reference range, 0.2-5.0 pg/mL) 7.1 (4.4) 4.3 (2.2) 4.9 (2.6) .0201
DHEA, ng/dL (reference range, 102-1185 ng/dL) 277 (109-892) 205 (114-914) 216 (113-481) .569
Adiponectin, µg/mL, mean (SD) (reference range, 5-28 mg/mL) 10.3 (4.2) 8.2 (3.9) 9.1 (4.9) .0508

*Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: BMI, body mass index; DHEA, dehydroepiandrosterone; T, testosterone.

Table 3.
Persistent Improvement in Serum Testosterone Level After Yoga Intervention
Test Yoga (0 mo) (n=9) Yoga (3 mo) (n=9) Yoga (6 mo) (n=9) P value*
Free T, pg/mL (reference range, 0.2-5.0 pg/mL) 7.1 (4.4) 4.3 (2.2) 4.9 (2.6) .0201
DHEA, ng/dL (reference range, 102-1185 ng/dL) 277 (109-892) 205 (114-914) 216 (113-481) .569
Adiponectin, µg/mL, mean (SD) (reference range, 5-28 mg/mL) 10.3 (4.2) 8.2 (3.9) 9.1 (4.9) .0508

*Statistical significance was set at P<.05, with P values between .05 and .10 considered trending.

Abbreviations: BMI, body mass index; DHEA, dehydroepiandrosterone; T, testosterone.

×